IN8bioINAB -0.45%24 EV-to-FCF is 0.45 as of Jun. 28, 2026. GuruFocus rates INAB with a GF Score™ of 24/100. Among 336 Biotechnology companies, IN8bio ranks better than 83.93% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, IN8bio's Enterprise Value is $-6.55 Mil.
IN8bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-14.55 Mil. Therefore, IN8bio's EV-to-FCF for today is 0.45.
The historical rank and industry rank for IN8bio's EV-to-FCF or its related term are showing as below:
INAB'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.45
Current: 0.45
During the past 8 years, the highest EV-to-FCF of IN8bio was 0.45. The lowest was 0.00. And the median was 0.00.
INAB's EV-to-FCF is ranked better than 83.93% of 336
companies
in the Biotechnology industry
Industry Median: 14.7
vs INAB: 0.45
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-06-28), IN8bio's stock price is $1.36.
IN8bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.856. Therefore, IN8bio's PE Ratio (TTM) for today is At Loss.
IN8bio (NAS:INAB) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
IN8bio's share price for today is $1.36.
IN8bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.856.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
IN8bio EV-to-FCF Related Terms
IN8bio EV-to-FCF Historical Data
* Premium members only.
The historical data trend for IN8bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, IN8bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IN8bio EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IN8bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where IN8bio's EV-to-FCF falls into.
IN8bio's current Enterprise Value is $-6.55 Mil.
IN8bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IN8bio (INAB) has a EV-to-FCF of 0.45 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on IN8bio and its competitors. According to the industry distribution chart, IN8bio ranks #54 out of 336 companies in the Biotechnology industry, placing it in the top 16.1%.
Is IN8bio's EV-to-FCF too high?
IN8bio's current EV-to-FCF is 0.45. The Biotechnology industry median EV-to-FCF is 14.70. IN8bio's value of 0.45 is 96.9% below this industry median. Based on the distribution chart, IN8bio ranks #54 out of 336 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, IN8bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does IN8bio's EV-to-FCF compare to ZIVO and LPCN?
According to the Biotechnology industry distribution chart, IN8bio ranks #54 out of 336 companies for EV-to-FCF. This places IN8bio in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 14.70. IN8bio's value of 0.45 is 96.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.70, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IN8bio's current EV-to-FCF of 0.45 is 96.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on IN8bio and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IN8bio's current EV-to-FCF is 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IN8bio stock overvalued right now?
IN8bio (INAB) has a current EV-to-FCF of 0.45. The current EV-to-FCF is 0.45 and 96.9% below the Biotechnology industry median of 14.70. IN8bio's overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For IN8bio (INAB), the current EV-to-FCF is 0.45 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
24GF Score
Get the complete analysis for INAB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INAB has been successfully added to your 
